Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
69 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Diabetic Neuropathy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Diabetic Neuropathy - Pipeline Review, H2 2014', provides an overview of the Diabetic Neuropathy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Diabetic Neuropathy Overview 7 Therapeutics Development 8 Pipeline Products for Diabetic Neuropathy - Overview 8 Pipeline Products for Diabetic Neuropathy - Comparative Analysis 9 Diabetic Neuropathy - Therapeutics under Development by Companies 10 Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 12 Diabetic Neuropathy - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Diabetic Neuropathy - Products under Development by Companies 15 Diabetic Neuropathy - Products under Investigation by Universities/Institutes 16 Diabetic Neuropathy - Companies Involved in Therapeutics Development 17 Sumitomo Dainippon Pharma Co., Ltd. 17 Neuralstem, Inc. 18 Lpath, Inc. 19 R-Tech Ueno, Ltd. 20 Neurotune AG 21 Omeros Corporation 22 Glucox Biotech AB 23 Vascular Pharmaceuticals, Inc. 24 Diabetic Neuropathy - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 ranirestat - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Lpathomab - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 NT-13317 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RTU-1096 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 NSI-566 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Stromal Cell Therapy For Diabetic Complications - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 VPI-2690-B - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Peptide to Activate MAS-GPCR for Diabetic Neuropathy - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecule for Diabetic Neuropathy and Retinopathy - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 BBI-21007 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Synthetic Peptides for Central Nervous System Disorders - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules for Diabetic Neuropathy - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Diabetic Neuropathy - Recent Pipeline Updates 51 Diabetic Neuropathy - Dormant Projects 59 Diabetic Neuropathy - Discontinued Products 60 Diabetic Neuropathy - Product Development Milestones 61 Featured News & Press Releases 61 Jun 26, 2014: BioDelivery Sciences Announces Completion of Patient Enrollment in its Initial Phase 3 Trial of Clonidine Topical Gel for Painful Diabetic Neuropathy 61 May 06, 2014: BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy 61 Apr 03, 2014: BioDelivery Sciences Announces Enrollment of the First Patient in a Phase 3 Clinical Study of Clonidine Topical Gel for Painful Diabetic Neuropathy 62 Dec 02, 2013: Positive FDA Meeting Confirms BDSI Phase 3 Program for Clonidine Topical Gel for Treatment of Painful Diabetic Neuropathy 63 Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 64 Nov 27, 2012: ChemoCentryx Announces Initiation Of Phase I Clinical Trial Of CCX872 65 Oct 15, 2012: Genkyotex Announces Presentation Of Data From Phase I Studies Of GKT137831 At Kidney Week 2012 65 Nov 07, 2011: NephroGenex Reaches Agreement With FDA On Subpart H Phase III Program For Pyridorin 65 Oct 31, 2011: J&JPRD Submits Supplemental New Drug Application To FDA For NUCYNTA ER Tablets For Diabetic Peripheral Neuropathic Pain 66 Oct 19, 2011: Concert Pharmaceuticals To Present Data On CTP-499 At American Society of Nephrology Kidney Week Meeting 66 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 69 Disclaimer 69
List of Tables Number of Products under Development for Diabetic Neuropathy, H2 2014 8 Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Diabetic Neuropathy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 17 Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H2 2014 18 Diabetic Neuropathy - Pipeline by Lpath, Inc., H2 2014 19 Diabetic Neuropathy - Pipeline by R-Tech Ueno, Ltd., H2 2014 20 Diabetic Neuropathy - Pipeline by Neurotune AG, H2 2014 21 Diabetic Neuropathy - Pipeline by Omeros Corporation, H2 2014 22 Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H2 2014 23 Diabetic Neuropathy - Pipeline by Vascular Pharmaceuticals, Inc., H2 2014 24 Assessment by Monotherapy Products, H2 2014 25 Number of Products by Stage and Target, H2 2014 27 Number of Products by Stage and Mechanism of Action, H2 2014 29 Number of Products by Stage and Route of Administration, H2 2014 31 Number of Products by Stage and Molecule Type, H2 2014 33 Diabetic Neuropathy Therapeutics - Recent Pipeline Updates, H2 2014 51 Diabetic Neuropathy - Dormant Projects, H2 2014 59 Diabetic Neuropathy - Discontinued Products, H2 2014 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
